Nanorepro: New revenue guidance reinforces growth trajectory; chg. est. - NuWays AG Research

Ahead of its AGM today, NanoRepro published group revenue guidance for the short-, medium- and long-term on Friday, providing greater visibility on the expected growth trajectory of its multi-brand health platform. In detail:

FY26 guidance confirms double-digit growth. Management guided for ~ € 18m in revenue, slightly
below our projection of € 19m (eNuW), but still confirming solid double-digit growth of ~ 12.5% yoy.
Growth is expected to be largely organic, as the current inorganic contribution from ALPHABIOL
should remain modest at ~ € 0.2m (eNuW) in FY26e.

Länk till analysen i sin helhet: https://www.nuways-ag.com/research/new-revenue-guidance-reinforces-growth-trajectory-chg-est